Drug Profile
Research programme: zirconium-89-conjugated imaging agents - Telix Pharmaceuticals
Latest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Telix Pharmaceuticals
- Developer Peter MacCallum Cancer Centre; Telix Pharmaceuticals; University of Melbourne
- Class Imaging agents; Protein diagnostics; Radioisotopes
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for research development in Cancer(Diagnosis) in Australia (Parenteral)
- 18 Oct 2017 Telix Pharmaceuticals and the University of Melbourne agree to co-develop zirconium-89-conjugated imaging agents in Australia for Prostate cancer, Renal cancer and Colorectal cancer
- 18 Oct 2017 Telix Pharmaceuticals in-licenses zirconium-89 protein conjugation technology from the University of Melbourne